Recent Advances in Allergic Rhinitis: A Narrative Review.

Autor:	Tidke M; Otolaryngology, Mahatama Gandhi Ayurveda College, Hospital and Research Centre, Wardha, IND., Borghare PT; Otolaryngology, Mahatama Gandhi Ayurveda College, Hospital and Research Centre, Wardha, IND., Pardhekar P; Otolaryngology, Mahatama Gandhi Ayurveda College, Hospital and Research Centre, Wardha, IND., Nasre Y; Otolaryngology, Bhausaheb Mulak Ayurved Mahavidyalaya & Medical Science & Research, Nagpur, IND., Gomase K; Obstetrics and Gynaecology, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Higher Education and Research, Wardha, IND., Chaudhary M; Nursing, Shalinitai Meghe College of Nursing, Datta Meghe Institute of Higher Education and Resesrach, Wardha, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Sep 04; Vol. 16 (9), pp. e68607. Date of Electronic Publication: 2024 Sep 04 (Print Publication: 2024).
DOI:	10.7759/cureus.68607
Abstrakt:	Allergic rhinitis (AR) is a prevalent chronic respiratory condition characterized by nasal inflammation, sneezing, congestion, and itching, significantly impacting quality of life. Over recent years, considerable advancements have been made in understanding the pathophysiology, diagnosis, and management of AR. This narrative review aims to synthesize these recent developments, providing a comprehensive overview of key areas. Emerging insights into AR pathophysiology have elucidated the complex interplay between genetic predisposition, environmental factors, and immune system dysregulation. Notably, the role of the epithelial barrier and the microbiome in AR pathogenesis has garnered increasing attention, offering potential targets for novel therapies. Advances in diagnostic technologies, such as component-resolved diagnostics and molecular allergology, have enhanced the precision of allergy identification, enabling more personalized treatment approaches. In terms of management, significant progress has been made in pharmacological and non-pharmacological treatments. Novel biologics targeting specific pathways involved in AR, including monoclonal antibodies against immunoglobulin (Ig)E and interleukin (IL)-4/13, have shown promise in reducing symptoms in refractory cases. Additionally, there has been a resurgence in interest in non-pharmacological strategies, including allergen avoidance, immunotherapy, and complementary therapies, which offer holistic options for patient care. The integration of digital health tools and mobile applications in AR management has further empowered patients, allowing for real-time symptom tracking and personalized treatment adjustments. Recent guidelines emphasize a multidisciplinary approach to AR management, promoting integrated care models that involve collaboration between allergists, primary care providers, and other specialists. These guidelines also highlight the importance of patient-centered care, advocating for shared decision-making and tailored treatment plans based on individual patient profiles. In conclusion, the landscape of allergic rhinitis management is rapidly evolving, with ongoing research and innovation paving the way for improved outcomes. This review underscores the importance of staying abreast of these advances to optimize the care and quality of life for individuals affected by allergic rhinitis. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Tidke et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu